Alexander co-authors study in Lancet Oncology

March 20, 2020

This was the first peer-reviewed study of venetoclax in a pediatric population, and first study using the drug with intensive acute myeloid leukemia chemotherapy.

Phase I study indicates drug could boost immune function in blood cancers

January 14, 2020

An early-stage clinical study investigating a method of boosting the body’s defenses against two blood cancers found the drug pomalidomide could be safely added to conventional treatments, and help improve immune function. University of North Carolina Lineberger Comprehensive Cancer Center researcher Joshua Zeidner, MD, assistant professor in the UNC School of Medicine Division of Hematology/Oncology, … Continued

Leukemia & Lymphoma Society grant supports drug discovery research

September 3, 2019

The Leukemia & Lymphoma Society has awarded a $971,484 Screen to Lead grant to University of North Carolina Lineberger Comprehensive Cancer Center researchers to launch an investigation of new drug compounds that would block enzymes that can become hyperactive in blood cancer cells when mutated. UNC Lineberger’s John Sondek, PhD, a professor in the UNC … Continued

Family ties remain strong even through cancer diagnosis

July 12, 2019

Jack Goldstein, 14, and his family had to make sacrifices when Jack was diagnosed with leukemia. But when Jack put his schoolwork and baseball training on hold, his family and friends were there to support him, first emotionally, and then by helping raise funds for UNC Lineberger, where he was being treated for cancer.

A caring cancer community: mom, daughter support other pediatric patients

May 10, 2019

Lorelei Partin’s cancer journey has led her mom, Katie Ware, to discover a whole new community of friends and a hidden talent for fundraising along the way. Diagnosed two years ago, Lorelei cannot wait to ring the bell to mark the end of her leukemia treatments, but she’s going to miss the people at the N.C. Cancer Hospital’s Pediatric Hematology Oncology Clinic, including her doctor, UNC Lineberger’s Thomas Alexander, MD, MPH.

Results ‘encouraging’ from phase II trial for relapsed acute myeloid leukemia

December 21, 2018

UNC Lineberger’s Joshua Zeidner, MD, reported preliminary data at the 60th American Society of Hematology Annual Meeting from a phase II clinical trial for administering a high-dose of the chemotherapy treatment cytarabine followed by an immune checkpoint inhibitor, pembrolizumab, in patients with acute myeloid leukemia that had relapsed or no longer responded to other treatment.